DocumentoJDRF Therapeutic Venturesenviado por
sstrumello7395- DocumentoGeneral Foods Corporate Timelineenviado porsstrumello7395
- DocumentoJDRF, Less Until Noneenviado porsstrumello7395
- DocumentoWhy Big Pharmaceutical Companies’ Current Nanotech Efforts Should Failenviado porsstrumello7395
- DocumentoNovo Nordisk Congressional Testimony on Follow-On Biopharmaceuticals Mollerup March 26, 2007enviado porsstrumello7395
- DocumentoEmblem Insulin Formulary Change 2010enviado porsstrumello7395
- DocumentoWhy Nonprofits Fund For-Profit Companies Doing Drug Researchenviado porsstrumello7395
- DocumentoAgaMatrix & Sanofi-Aventis Enter Global Diabetes Partnershipenviado porsstrumello7395
- DocumentoHuman insulin prepared by recombinant DNA techniques and native human insulin interact identically with insulin receptorsenviado porsstrumello7395
- DocumentoFDA ISO Standards for BG Meters 06-24-2009enviado porsstrumello7395
- DocumentoBeyond 'I'm a Diabetic', Little Common Groundenviado porsstrumello7395
- DocumentoHalozyme Therapeutics, Inc. 2009 Investor Day Presentationenviado porsstrumello7395
- DocumentoJDRF Countdown July 2009enviado porsstrumello7395
- Documento2008-03-24_Asset_EN Paper on Follow-On Biologics Jan. 2007enviado porsstrumello7395
- Documento2008-03-24_Asset_PCMA Summary of en Studyenviado porsstrumello7395
- DocumentoInfluence of insulin antibodies on pharmacokinetics and bioavailability of recombinant human and highly purified beef insulins in insulin dependent diabeticsenviado porsstrumello7395
- DocumentoThe Unique Cytoarchitechture of Human Pancreatic Islets Has Implications for Islet Cell Functionenviado porsstrumello7395
- DocumentoStatement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings on "Follow-On Biopharmaceuticals"enviado porsstrumello7395
- DocumentoMost Commercial Insulin Assays Fail to Detect Recombinant Insulin Analoguesenviado porsstrumello7395
- DocumentoHow Do We Define Cure of Diabetes?enviado porsstrumello7395
- DocumentoExpanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin isotopeenviado porsstrumello7395
- DocumentoCould Generic Insulin Soon Hit the U.S. Market?enviado porsstrumello7395
- DocumentoClass Action Complaint for Negligence, Products Liability and Punitive Damages Against Eli Lilly & Company and Novo Nordisk A/S Re; Biosynthetic Human Insulinenviado porsstrumello7395
- DocumentoMandated Diabetes Registries Will Not Benefit Persons With Diabetesenviado porsstrumello7395
- DocumentoDetermination of Purity and Identification of Animal Sources of Insulin in Various Insulin Preparationsenviado porsstrumello7395
- DocumentoPeter Van Etten JDRF Letter Reenviado porsstrumello7395
- DocumentoTreatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 yearsenviado porsstrumello7395
- DocumentoDifferent Potencies of Biosynthetic Human and Purified Porcine Insulinenviado porsstrumello7395
- DocumentoQuestions Answers &enviado porsstrumello7395
- DocumentoStem Cells and Diabetesenviado porsstrumello7395
- DocumentoFederal Funding of Stem Cell Researchenviado porsstrumello7395
Escolar Documentos
Profissional Documentos
Cultura Documentos
